Scribe Therapeutics launched a second-half IPO push with a rare gene-editing listing priced to raise about $128.7 million, above initial expectations. The in vivo gene editing company priced 8.6 million shares at $15 each for Nasdaq trading under the ticker “SCTX.” The proceeds are set to fund early clinical execution for STX-1150, a PCSK9-silencing program designed for patients with elevated cholesterol and atherosclerotic cardiovascular disease risk. The company also earmarked capital for additional cardiovascular programs targeting APOC3 and LPA. The IPO comes as gene editing attempts to sustain public-market attention after a muted stretch for the category, and it signals that investors are willing to underwrite platform-like genetics franchises moving into cardiometabolic indications. The immediate next milestone is topline Phase 1 data timing in 2027, alongside ongoing momentum in the PCSK9 oral and genetic space.